Michael W Deininger

Michael W Deininger

UNVERIFIED PROFILE

Are you Michael W Deininger?   Register this Author

Register author
Michael W Deininger

Michael W Deininger

Publications by authors named "Michael W Deininger"

Are you Michael W Deininger?   Register this Author

100Publications

3194Reads

10Profile Views

Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.

N Engl J Med 2019 12;381(24):2315-2326

From the South Australian Health and Medical Research Institute and the University of Adelaide, Adelaide, SA, Australia (T.P.H., D.Y., D.M.R.); Memorial Sloan Kettering Cancer Center, New York (M.J.M., M.S.T., J.H.P.); University of Texas M.D. Anderson Cancer Center, Houston (J.E.C.); Kobe University Graduate School of Medicine, Kobe (H.M.), and the National Cancer Center Hospital East, Chiba (Y.M.) - both in Japan; Hôpital Saint-Louis, Paris (D.R.), and the University of Bordeaux, Bordeaux (F.-X.M.) - both in France; Dana-Farber Cancer Institute, Boston (D.J.D.); Sapienza University, Rome (M.B.); Singapore General Hospital, Singapore (Y.-T.G.); University of Michigan Comprehensive Cancer Center, Ann Arbor (M.T.); Universitätsklinikum Jena, Jena (A.H.), Charité Hospital, Berlin (P.C.), and the Department for Hematology-Oncology, Goethe University Hospital, Frankfurt am Main (F.L.) - all in Germany; University of Cardiff, Cardiff, United Kingdom (O.O.); Veterans Affairs Portland Health Care System (M.C.H.) and Oregon Health and Science University Knight Cancer Institute (M.C.H., B.J.D.), Portland; Hospital de la Princesa and Instituto de Investigación Sanitaria Princesa, Madrid (J.L.S.); Huntsman Cancer Institute, University of Utah, Salt Lake City (M.W.N.D.); Amsterdam University Medical Centers, VU University Medical Center, Amsterdam (J.J.W.M.J.); Novartis Pharma, Basel, Switzerland (D.H., Y.D., C.M., F.H.-P., K.G.V.); and Seoul St. Mary's Hematology Hospital, Catholic University of Korea, Seoul, South Korea (D.-W.K.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1902328DOI Listing
December 2019

ddeeper Than Deep: Can ddPCR Predict Successful Imatinib Cessation?

Clin Cancer Res 2019 Nov 20;25(22):6561-6563. Epub 2019 Sep 20.

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-19-2270DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858959PMC
November 2019

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.

Exp Hematol 2019 09 4;77:36-40.e2. Epub 2019 Sep 4.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2019.08.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6803074PMC
September 2019

Lysozyme nephropathy in chronic myelomonocytic leukemia.

Clin Case Rep 2019 Jun 10;7(6):1263-1264. Epub 2019 May 10.

Division of Hematology and Hematologic Malignancies University of Utah Salt Lake City Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2188DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6553339PMC
June 2019

Drug-free macromolecular therapeutics induce apoptosis in cells isolated from patients with B cell malignancies with enhanced apoptosis induction by pretreatment with gemcitabine.

Nanomedicine 2019 02 9;16:217-225. Epub 2019 Jan 9.

Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT, USA; Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nano.2018.12.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6408272PMC
February 2019

Functional genomic landscape of acute myeloid leukaemia.

Nature 2018 10 17;562(7728):526-531. Epub 2018 Oct 17.

Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41586-018-0623-zDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6280667PMC
October 2018

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial.

J Clin Oncol 2018 01 1;36(3):231-237. Epub 2017 Nov 1.

Jorge E. Cortes, University of Texas MD Anderson Cancer Center, Houston, TX; Carlo Gambacorti-Passerini, University of Milano-Bicocca, Monza, Italy; Michael W. Deininger, University of Utah, Salt Lake City, UT; Michael J. Mauro, Memorial Sloan Kettering Cancer Center, New York, NY; Charles Chuah, Singapore General Hospital, Duke-National University of Singapore Medical School, Singapore, Singapore; Dong-Wook Kim, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea; Irina Dyagil, National Research Center for Radiation Medicine, Kiev; Nataliia Glushko, Ivano-Frankivsk Regional Clinical Hospital, Ivano-Frankivsk, Ukraine; Dragana Milojkovic, Imperial College London at Hammersmith Hospital London; Laurence Reilly and Allison Jeynes-Ellis, Avillion, London, United Kingdom; Philipp le Coutre, Charité-Universitätsmedizin Berlin, Berlin; Andreas Hochhaus, Klinik für Innere Medizin II, Universitätsklinikum Jena, Jena; Tim H. Brümmendorf, Universitätsklinikum RWTH Aachen, Aachen, Germany; Valentin Garcia-Gutierrez, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria, Madrid, Spain; Eric Leip, Pfizer, Cambridge, MA; Nathalie Bardy-Bouxin, Pfizer International Operation, Paris, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.7162DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5966023PMC
January 2018

Minimal Residual Disease Eradication in CML: Does It Really Matter?

Curr Hematol Malig Rep 2017 10;12(5):495-505

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Hospital, The University of Utah, Salt Lake City, UT, 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-017-0409-7DOI Listing
October 2017

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.

Hematol Oncol Clin North Am 2017 08;31(4):589-612

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, The University of Utah, 2000 Circle of Hope Drive, Salt Lake City, UT 84112, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2017.04.007DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5505321PMC
August 2017

Treating the chronic-phase chronic myeloid leukemia patient: which TKI, when to switch and when to stop?

Expert Rev Hematol 2017 07 22;10(7):659-674. Epub 2017 May 22.

c Division of Hematology and Hematologic Malignancies , Huntsman Cancer Institute, The University of Utah , Salt Lake City , UT , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/17474086.2017.1330144DOI Listing
July 2017

Turning the tide in myelodysplastic/myeloproliferative neoplasms.

Nat Rev Cancer 2017 06;17(7):425-440

INSERM U1170, Gustave Roussy, Faculté de médecine Paris-Sud, Université Paris-Saclay, F-94805 Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc.2017.40DOI Listing
June 2017

Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

N Engl J Med 2017 03;376(10):917-927

From Abteilung Hämatologie-Onkologie, Universitätsklinikum Jena, Jena, Germany (A.H.); the Department of Medicine, University of Chicago, Chicago (R.A.L.); INSERM Centre d'Investigation Clinique 1402, Centre Hospitalier Universitaire de Poitiers, Poitiers, France (F.G.); Fred Hutchinson Cancer Research Center, Seattle (J.P.R.); Centre for Cancer Biology, SA Pathology, University of South Australia and University of Adelaide (S.B.), and the South Australian Health and Medical Research Institute and University of Adelaide (T.P.H.), Adelaide, SA, Australia; University of Bologna, Bologna, Italy (M.B.); the University of Utah Huntsman Cancer Institute, Salt Lake City (M.W.D.); the Hematology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona (F.C.); Novartis, Basel, Switzerland (S.F., C.-E.O., H.D.M.); M.D. Anderson Cancer Center, Houston (H.K.); the University of Newcastle, Newcastle, United Kingdom (S.G.O.); and Knight Cancer Institute, Oregon Health and Science University and Howard Hughes Medical Institute, Portland (B.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1609324DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5901965PMC
March 2017

Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia.

Cell Rep 2017 03;18(13):3204-3218

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA; Department of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR 97239, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2017.03.018DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437102PMC
March 2017

Molecular monitoring in CML and the prospects for treatment-free remissions.

Hematology Am Soc Hematol Educ Program 2015 ;2015:257-63

Huntsman Cancer Institute, The University of Utah, Salt Lake City, Utah; and Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/asheducation-2015.1.257DOI Listing
October 2016

Cross-Intolerance With Dasatinib Among Imatinib-Intolerant Patients With Chronic Phase Chronic Myeloid Leukemia.

Clin Lymphoma Myeloma Leuk 2016 06 29;16(6):341-349.e1. Epub 2016 Mar 29.

Department of Oncology, Hematology, and Cell Therapy, Centre Hospitalier Universitaire de Poitiers, Clinical Investigation Center, Inserm 0802, Poitiers, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2016.03.004DOI Listing
June 2016

New Strategies in Myeloproliferative Neoplasms: The Evolving Genetic and Therapeutic Landscape.

Clin Cancer Res 2016 Mar;22(5):1037-47

Chief of Hematology, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826348PMC
March 2016

Diagnosing and managing advanced chronic myeloid leukemia.

Am Soc Clin Oncol Educ Book 2015 :e381-8

From the Huntsman Cancer Institute, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.14694/EdBook_AM.2015.35.e381DOI Listing
February 2016

Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients.

Blood 2016 Feb 24;127(6):703-12. Epub 2015 Nov 24.

Department of Genetics and Molecular Pathology, SA Pathology, Centre for Cancer Biology, School of Medicine and School of Molecular and Biomedical Science, University of Adelaide, Adelaide, Australia; and School of Pharmacy and Medical Science, University of South Australia, Adelaide, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1182/blood-2015-08-660977DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4760131PMC
February 2016

Structural insight into selectivity and resistance profiles of ROS1 tyrosine kinase inhibitors.

Proc Natl Acad Sci U S A 2015 Sep 8;112(39):E5381-90. Epub 2015 Sep 8.

Division of Hematology and Medical Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239; Howard Hughes Medical Institute, Portland, OR 97239;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1515281112DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4593101PMC
September 2015

Limited efficacy of BMS-911543 in a murine model of Janus kinase 2 V617F myeloproliferative neoplasm.

Exp Hematol 2015 Jul 24;43(7):537-45.e1-11. Epub 2015 Apr 24.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA; Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.exphem.2015.03.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4487517PMC
July 2015

Systemic mastocytosis in a patient with Cowden syndrome.

Am J Hematol 2014 Dec 27;89(12):1154. Epub 2014 Aug 27.

Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ajh.23815DOI Listing
December 2014

Response monitoring, tolerability, and effectiveness of imatinib treatment for chronic myeloid leukemia in a retrospective research database.

J Natl Compr Canc Netw 2014 Aug;12(8):1113-21

From the Department of Pharmacotherapy, University of Utah, and Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City, Utah; Novartis Pharmaceuticals, East Hanover, New Jersey; and the Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Health Care, and University of Utah Program in Personalized Health Care, Salt Lake City, Utah.From the Department of Pharmacotherapy, University of Utah, and Huntsman Cancer Institute, University of Utah Health Care, Salt Lake City, Utah; Novartis Pharmaceuticals, East Hanover, New Jersey; and the Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah Health Care, and University of Utah Program in Personalized Health Care, Salt Lake City, Utah.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.6004/jnccn.2014.0108DOI Listing
August 2014

KIT signaling governs differential sensitivity of mature and primitive CML progenitors to tyrosine kinase inhibitors.

Cancer Res 2013 Sep 25;73(18):5775-86. Epub 2013 Jul 25.

Authors' Affiliations: OHSU Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon; Howard Hughes Medical Institute, Chevy Chase, Maryland; Huntsman Cancer Institute; Division of Hematology and Hematologic Malignancies, The University of Utah, Salt Lake City, Utah; Novartis Institutes for BioMedical Research, Basel, Switzerland; and Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-13-1318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3894913PMC
September 2013

Engineering a BCR-ABL-activated caspase for the selective elimination of leukemic cells.

Proc Natl Acad Sci U S A 2013 Feb 16;110(6):2300-5. Epub 2013 Jan 16.

Department of Pharmacology and Toxicology, Geisel School of Medicine, Dartmouth College, Hanover, NH 03755, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1206551110DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3568344PMC
February 2013

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

Nat Rev Cancer 2012 Jul 24;12(8):513-26. Epub 2012 Jul 24.

Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Salt Lake City, Utah 84112, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nrc3317DOI Listing
July 2012

Development of an effective therapy for chronic myelogenous leukemia.

Cancer J 2011 Nov-Dec;17(6):477-86

Departments of Pharmacology and Toxicology, College of Pharmacy, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PPO.0b013e318237e5b7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251313PMC
June 2012

What do kinase inhibition profiles tell us about tyrosine kinase inhibitors used for the treatment of CML?

Leuk Res 2012 Mar 11;36(3):253-61. Epub 2011 Oct 11.

Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112-5550, USA.

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01452126110046
Publisher Site
http://dx.doi.org/10.1016/j.leukres.2011.09.018DOI Listing
March 2012

Selection of therapy: rational decisions based on molecular events.

Hematol Oncol Clin North Am 2011 Oct;25(5):1009-23, vi

Deininger Lab, Huntsman Cancer Institute, University of Utah, 2000 Circle of Hope, Room 4270, Salt Lake City, UT 84112-5550, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.hoc.2011.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3251311PMC
October 2011

Advances in the treatment of chronic myeloid leukemia.

BMC Med 2011 Aug 26;9:99. Epub 2011 Aug 26.

Division of Hematology and Hematologic Malignancies, University of Utah Huntsman Cancer Institute, Salt Lake City, Utah, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1741-7015-9-99DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3182901PMC
August 2011

Targeting the BCR-ABL signaling pathway in therapy-resistant Philadelphia chromosome-positive leukemia.

Clin Cancer Res 2011 Jan 22;17(2):212-21. Epub 2010 Nov 22.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-3314DOI Listing
January 2011

Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.

J Clin Invest 2011 Jan 13;121(1):396-409. Epub 2010 Dec 13.

Division of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute, Portland, Oregon, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI35721DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3007128PMC
January 2011

Resistance to imatinib: mutations and beyond.

Semin Hematol 2010 Oct;47(4):335-43

Klinik für Innere Medizin II, Hämatologie/Onkologie, Universitätsklinikum Jena, Jena, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2010.06.005DOI Listing
October 2010

A specific need for CRKL in p210BCR-ABL-induced transformation of mouse hematopoietic progenitors.

Cancer Res 2010 Sep 31;70(18):7325-35. Epub 2010 Aug 31.

Ben May Department for Cancer Research, Committees on Developmental Biology, Genetics, Cancer Biology, and Cell Physiology, University of Chicago, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0607DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940946PMC
September 2010

How much and how long: tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

Clin Lymphoma Myeloma Leuk 2010 Jun;10 Suppl 1:S20-6

Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLML.2010.s.003DOI Listing
June 2010

Molecular diagnostics in chronic myeloid leukemia.

Expert Opin Med Diagn 2010 Mar;4(2):113-24

Abteilung für Hämatologie, Onkologie und Hämostaseologie, Universitätsklinikum Leipzig, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/17530050903483187DOI Listing
March 2010

A BCR-ABL mutant lacking direct binding sites for the GRB2, CBL and CRKL adapter proteins fails to induce leukemia in mice.

PLoS One 2009 Oct 13;4(10):e7439. Epub 2009 Oct 13.

Division of Hematology and Medical Oncology, Oregon Health & Science University Knight Cancer Institute, Portland, Oregon, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0007439PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757918PMC
October 2009

Management of drug toxicities in chronic myeloid leukaemia.

Best Pract Res Clin Haematol 2009 Sep;22(3):409-29

Knight Cancer Institute, Center For Hematologic Malignancies, Oregon Health & Science University, 3181 SW Sam Jackson Park Road, UHN-73C, Portland, OR 97239, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.beha.2009.06.001DOI Listing
September 2009